Detalhe da pesquisa
1.
Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
J Hepatol
; 74(2): 274-282, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33038432
2.
A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis.
J Hepatol
; 72(5): 816-827, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31887369
3.
Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
J Hepatol
; 72(5): 885-895, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31870950
4.
Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.
Hepatology
; 69(2): 717-728, 2019 02.
Artigo
Inglês
| MEDLINE | ID: mdl-30063802
5.
Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-Stage Liver Disease Scores Compared With Placebo.
Clin Gastroenterol Hepatol
; 17(4): 774-783.e4, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29913280
6.
Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease.
Aliment Pharmacol Ther
; 49(1): 64-73, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30430605
7.
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition.
N Engl J Med
; 353(11): 1114-23, 2005 Sep 15.
Artigo
Inglês
| MEDLINE | ID: mdl-16162882
8.
A Placebo-Controlled, Multicenter, Double-Blind, Phase 2 Randomized Trial of the Pan-Caspase Inhibitor Emricasan in Patients with Acutely Decompensated Cirrhosis.
J Clin Exp Hepatol
; 8(3): 224-234, 2018 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-30302038
9.
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.
N Engl J Med
; 349(20): 1907-15, 2003 Nov 13.
Artigo
Inglês
| MEDLINE | ID: mdl-14614165
10.
Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Arthritis Res Ther
; 18(1): 214, 2016 10 03.
Artigo
Inglês
| MEDLINE | ID: mdl-27716403
11.
Erratum to: Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney.
Arthritis Res Ther
; 18(1): 236, 2016 10 12.
Artigo
Inglês
| MEDLINE | ID: mdl-27733209